Product
Recombinant Novel Coronavirus Vaccine
Aliases
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
3 clinical trials
1 indication
Indication
COVID-19Clinical trial
Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult VolunteersStatus: Completed, Estimated PCD: 2021-06-19
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2022-07-08
Clinical trial
A Multicenter, Randomized, and Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of Intramuscular and Inhaled COVID-19 Vaccine in Children Aged 6-12 Years and Adolescents Aged 13-17 Years Who Have Been Immunized With Two Doses of CoronaVacStatus: Terminated, Estimated PCD: 2023-01-13